Mark Charles Hayes

US Patent:

8496961, Jul 30, 2013

Filed:

May 15, 2003

Appl. No.:

10/439856

Inventors:

Keelung Hong - San Francisco CA, US
Wei-Wen Zheng - Las Vegas NV, US
Daryl C. Drummond - Concord CA, US
Dmitri B. Kirpotin - San Francisco CA, US
Mark Eamon Hayes - San Francisco CA, US

Assignee:

Sutter West Bay Hospital - San Francisco CA

International Classification:

A61K 9/127

US Classification:

424450, 424489, 424490, 264 41

Abstract:

A process for preparing a microparticulate complex is provided. The process comprises (a) combining a particle-forming component (“PFC”) and a nucleic acid-like component (“NAC”) in a monophasic composition comprising water and a water-miscible, organic solvent to form a mixture wherein the PFC and the NAC are independently molecularly or micellarly soluble in the aqueous/organic solvent system, and (b) reducing the amount of the organic solvent in the mixture. This effects formation of the microparticulate complex of the NAC and the PFC. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component forming an approximately spherical particle, wherein the particle-forming component encloses an interior of the particle containing the nucleic acid-like component and the so-enclosed interior volume has less than about 50% (preferably less than 20%) of the volume containing free water.

US Patent:

20090078326, Mar 26, 2009

Filed:

Jun 14, 2005

Appl. No.:

11/629365

Inventors:

Rohit Rosario - Mountain View CA, US
Mark Hayes - Gilbert AZ, US
Antonio A. Garcia - Chandler CA, US

Assignee:

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY - Tempe AZ

International Classification:

B81B 7/02
B32B 3/30
C23C 16/44
B05D 3/10
C12M 3/00

US Classification:

137827, 428172, 4272481, 427299, 422100, 137806, 137833

Abstract:

Disclosed are compositions and methods for producing movement of liquid across surfaces.

US Patent:

20090171077, Jul 2, 2009

Filed:

Mar 10, 2009

Appl. No.:

12/401454

Inventors:

Keelung Hong - San Francisco CA, US
Wei-Wen Zheng - Las Vegas CA, US
Daryl C. Drummond - Concord CA, US
Dmitri B. Kirpotin - San Francisco CA, US
Mark Eamon Hayes - San Francisco CA, US

International Classification:

C07H 21/00

US Classification:

536 253

Abstract:

A process for preparing a microparticulate complex is provided. The process comprises (a) combining a particle-forming component (“PFC”) and a nucleic acid-like component (“NAC”) in a monophasic composition comprising water and a water-miscible, organic solvent to form a mixture wherein the PFC and the NAC are independently molecularly or micellarly soluble in the aqueous/organic solvent system, and (b) reducing the amount of the organic solvent in the mixture. This effects formation of the microparticulate complex of the NAC and the PFC. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component forming an approximately spherical particle, wherein the particle-forming component encloses an interior of the particle containing the nucleic acid-like component and the so-enclosed interior volume has less than about 50% (preferably less than 20%) of the volume containing free water. Also disclosed composition comprising water and particles of the microparticulate complex. According to the invention a nucleic acid-like component is delivered to a cell by (a) contacting the cell with a composition comprising water and the microparticulate complex, and (b) maintaining the contact for a time sufficient to allow the nucleic acid-based moiety to enter the cell. A therapeutic nucleic acid-like component is delivered into a patient in need thereof by administering a composition comprising water and particles of the microparticulate complex. Also disclosed is a charge-changing composition represented by the formula A-X-B, wherein X represents a chemical bond capable of irreversible dissociation in reaction to a factor in a physiological or bioprocess environment; A represents a molecular moiety that upon dissociation of the bond X produces a ionically charged product; and B represents a molecular moiety, which upon the dissociation of bond X, separates from the composition leaving the remaining ionically charged product more positive than that of A-X-B itself.

US Patent:

20140017300, Jan 16, 2014

Filed:

Jul 11, 2013

Appl. No.:

13/940116

Inventors:

Keelung Hong - San Francisco CA, US
Wei-Wen Zheng - Las Vegas NV, US
Daryl C. Drummond - Concord CA, US
Dmitri B. Kirpotin - San Francisco CA, US
Mark Eamon Hayes - San Francisco CA, US

Assignee:

Sutter West bay Hospital, DBA California Pacific Medical Center - San Francisco CA

International Classification:

A61K 9/127
A61K 31/711

US Classification:

424450, 424400, 514 44 R

Abstract:

Provided herein is a process for preparing a microparticulate complex of a particle-forming component (“PFC”) and a nucleic acid-like component (“NAC”) in a monophasic composition comprising water and a water-miscible organic solvent. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component, and a composition comprising water and the microparticulate complex. Further provided is a method of delivery of a nucleic acid-like component to a cell or to a patient by contacting the cell with or administering to the patient a composition comprising water and the microparticulate complex described herein. Still further, a charge-changing composition represented by the formula A-X—B is provided.

US Patent:

20220411394, Dec 29, 2022

Filed:

Aug 8, 2022

Appl. No.:

17/818052

Inventors:

- Boxford MA, US
Dmitri B. Kirpotin - San Francisco CA, US
Mark E. Hayes - Mill Valley CA, US
Ross B. Fulton - Southborough MA, US

Assignee:

Akagera Medicines, Inc. - Boxford MA

International Classification:

C07D 317/28

Abstract:

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.

US Patent:

20230126953, Apr 27, 2023

Filed:

Dec 12, 2022

Appl. No.:

18/064565

Inventors:

- Boxford MA, US
Dmitri B. Kirpotin - San Francisco CA, US
Mark E. Hayes - Mill Valley CA, US

Assignee:

Akagera Medicines, Inc. - Boxford MA

International Classification:

C11C 3/00
C07F 9/09
C07D 317/28

Abstract:

The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.

US Patent:

20180296484, Oct 18, 2018

Filed:

Oct 15, 2016

Appl. No.:

15/768352

Inventors:

- Wrexham, GB
- Cambridge MA, US
Mark Eamon Hayes - MILL VALLEY CA, US
Charles Noble - SAN FRANCISCO CA, US
Kevin Kesper - WATERTOWN MA, US
Antoine M. Awad - WEST ROXBURY MA, US
Douglas J. Moore - NEWTON MA, US
Andrew J. O'Brien - FRANKLIN MA, US

International Classification:

A61K 9/127
A61K 31/4745

Abstract:

Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.

US Patent:

20170239182, Aug 24, 2017

Filed:

Aug 12, 2015

Appl. No.:

15/503004

Inventors:

Mark E. HAYES - San Francisco CA, US
Charles O. NOBLE - San Francisco CA, US
- San Francisco CA, US

International Classification:

A61K 9/127
A61K 31/4196
A61K 31/16

Abstract:

The present invention provides liposomes loaded with chelating agents, pharmaceutical formulations including these liposomes and methods of making chelating agent liposomes. Because the chelating agents are loaded in the liposome with high efficiencies, the liposomes are of use in treatment of metal ion overload in subjects. The liposomes can also contain essential trace metals to compensate for the off target effect of removal of endogenous non-target trace metals by administration of the chelator. The liposomes can include two or more different chelating agents of different structures and affinities for metal ions.